β谷固醇

β谷固醇

β谷固醇的功能

β谷固醇是在植物中发现的一种有机化合物，单独或联合植物甾醇使用时可以减少血液中胆固醇的水平。^{[1 2 3]}

减少胆固醇的原因可能是由于β谷固醇阻止胆固醇的吸收。^[4]它还能减轻良性前列腺增生的症状。^[5]尽管与β谷固醇相似的分子在试管试验中可以抑制癌细胞增长，但这一相关证据还不十分清楚。^[6]

β谷固醇的分布

β谷固醇是几乎所有植物中含有的几个植物甾醇之一（胆固醇是组要的动物甾醇）。米糠、小麦胚、玉米油、大豆、花生及其产物如花生油、花生酱、花生面都富含植物甾醇，尤其是β谷固醇。^[7]

β谷固醇认为与以下疾病有关（以下所有信息适用于个体化健康情况）：

哪些人可能会缺乏β谷固醇？

因为β谷固醇不是非必需营养素，所以不会缺乏。

一般需要多少β谷固醇？

临床研究中用每天500毫克~10克的β谷固醇来降低胆固醇水平。有报道称每天服用60~130毫克来减轻良性前列腺增生的症状。^{[8 9]}

是否有副作用和药物相互作用？

目前还没有关于β谷固醇副作用的相关报道。

到目前为止，还不知道β谷固醇与其他药物间的相互作用。

参考文献

1. Stanley RG, Liskens HF. Pollens. Springer-Verlag: New York, 1974.

2. Loschen G, Ebeling L. Inhibition of arachidonic acid cascade by extract of rye pollen. Arzneimittelforschung 1991;41:162–7 [in German].

3. Nakase K, Takenaga K, Hamanaka T, et al. Inhibitory effect and synergism of cernitin pollen extract on the urethral smooth muscle and diaphragm of the rat. Nippon Yakurigaku Zasshi 1988 Jun;91:385–92 [in Japanese].

4. Habib FK, Ross M, Buck AC, et al. In vitro evaluation of the pollen extract, cernitin T-60, in the regulation of prostate cell growth. Br J Urol 1990;66:393–7.

5. Jodai A, Maruta N, Shimomae E, et al. A long-term therapeutic experience with Cernilton in chronic prostatitis. Hinyokika Kiyo 1988;34:561–8 [in Japanese].

6. Ohkoshi M, Kawamura N, Nagakubo I. Clinical evaluation of Cernilton in chronic prostatitis. Jpn J Clin Urol 1967;21:73–6.

7. Suzuki T, Kurokawa K, Mashimo T, et al. Clinical effect of Cernilton in chronic prostatitis. Hinyokika Kiyo 1992;38:489–94 [in Japanese].

8. Rugendorff EW, Weidner W, Ebeling L, et al. Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia. Br J Urol 1993;71:433–8.

9. Horii A, Iwai S, Maekawa M, Tsujita M. Clinical evaluation of Cernilton in the treatment of the benign prostatic hypertrophy. Hinyokika Kiyo 1985;31:739–46 [in Japanese].

10. Ueda K, Jinno H, Tsujimura S. Clinical evaluation of Cernilton? on benign prostatic hyperplasia. Hinyokika Kiyo 1985;31:187–91 [in Japanese].

11. Hayashi J, Mitsui H, Yamakawa G, et al. Clinical evaluation of Cernilton in benign prostatic hypertrophy. Hinyokika Kiyo 1986;32:135–41 [in Japanese].

12. Becker H, Ebeling L. Conservative therapy of benign prostatic hyperplasia (BPH) with Cernilton. Urologe (B) 1988;28:301–6 [in German].

13. Buck AC, Cox R, Rees RW, et al. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernilton. A double-blind, placebo-controlled study. Br J Urol 1990;66:398–404.

14. Maekawa M, Kishimoto T, Yasumoto R, et al. [Clinical evaluation of Cernilton on benign prostatic hypertrophy—a multiple center double-blind study with Paraprost]. Hinyokika Kiyo 1990;36:495–516 [in Japanese].

15. Voloshyn OI, Pishak OV, Seniuk BP, et al. The efficacy of flower pollen in patients with rheumatoid arthritis and concomitant diseases of the gastroduodenal and hepatobiliary systems. Likarska Sprava 1998;4:151–4 [in Ukrainian].

16. Vourdas D, Syrigou E, Potamianou P, et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998;53:662–72.

17. Horak F, Stubner P, Berger UE, et al. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. J Investig Allergol Clin Immunol 1998;8:165–71.

18. Ariano R, Panzani RC, Augeri G. Efficacy and safety of oral immunotherapy in respiratory allergy to Parietaria judaica pollen. A double-blind study. J Investig Allergol Clin Immunol 1998;8:155–60.

19. Clavel R, Bousquet J, Andre C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 1998;5:493–8.

20. Litwin A, Flanagan M, Entis G, et al. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study. J Allergy Clin Immunol 1997;100:30–8.

21. Hordijk GJ, Antvelink JB, Luwema RA. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study. Allergol Immunopathol (Madr) 1998;26:234–40.

22. Kristoffersen K, Thomsen BW, Schacke E, Wagner HH. Use of natural medicines in women referred to specialists. Ugeskr Laeger 1997;159:294–6 [in Danish].

23. Szanto E, Gruber D, Sator M, et al. Placebo-controlled study of melbrosia in treatment of climacteric symptoms. Wien Med Wochenschr 1994;144:130–3 [in German].

24. Einer-Jensen N, Zhao J, Andersen KP, Kristoffersen K. Cimicifuga and Melbrosia lack oestrogenic effects in mice and rats. Maturitas 1996;25:149–53.

25. Cohen SH, Yunginger JW, Rosenberg N, Fink JN. Acute allergic reaction after composite pollen ingestion. J Allergy Clin Immunol 1979;64:270.

26. Mansfield LE, Goldstein GB. Anaphylactic reaction after ingestion of local bee pollen. Ann Allergy 1981;47:154–6.

27. Noyes JH, Boyd GK, Settipane GA. Anaphylaxis to sunflower seed. J Allergy Clin Immunol 1979;63:242–4.